TG Therapeutics, Inc. (TGTX)Healthcare | Biotechnology | Morrisville, United States | NasdaqCM
53.93 USD
-1.79
(-3.212%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 54.03 +0.10 (0.185%) ⇧ (Aug. 28, 2026, 7:46 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:31 a.m. EDT
The immediate outlook is driven by a powerful convergence of clinical success and aggressive speculative positioning. Recent headlines confirm a key drug exceeded expectations, triggering a surge in call volume at strikes above the current price, which signals that traders are betting on further appreciation rather than just hedging against a drop. While the statistical forecasting model offers only a weak lean upward due to low confidence, the fundamental reality is starkly different: the company is delivering 70% revenue growth and expanding margins, supported by a fortress-like balance sheet with a current ratio of 4.27 and zero debt pressure relative to cash. The stock has already rallied significantly over the last year, yet it remains well below its analyst mean target, leaving room for multiple expansion. The absence of a dividend is irrelevant here; this is a pure growth vehicle where capital allocation is reinvested into R&D. The only caution is the high beta and the fact that biotech valuations can be volatile, but the data suggests a high-conviction setup for the near term. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.047104 |
| AutoETS | 0.047131 |
| MSTL | 0.047686 |
| AutoTheta | 0.116864 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 1.89 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.223 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 124.89 |
| Revenue per Share | 5.61 |
| Market Cap | 8,255,014,400 |
| Trailing P/E | 20.35 |
| Forward P/E | 18.19 |
| Beta | 1.67 |
| Profit Margins | 55.22% |
| Website | https://www.tgtherapeutics.com |
As of Aug. 22, 2026, 2:31 a.m. EDT: Speculators are aggressively positioning for upside, evidenced by massive volume spikes in out-of-the-money calls (strikes $60-$65) where volume exceeds open interest, indicating fresh buying rather than hedging. Conversely, put writing is heavy at lower strikes ($25-$40), creating a 'floor' for downside protection while allowing for unlimited upside. Implied volatility is elevated on deep OTM calls, suggesting the market prices in a binary event or significant catalyst, though the lack of deep ITM call volume suggests this is speculative rather than a guaranteed bet on a massive rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8742012 |
| Address1 | 3,020 Carrington Mill Blvd. |
| Address2 | Suite 475 |
| All Time High | 233.4375 |
| All Time Low | 0.95625 |
| Ask | 61.42 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 1,963,130 |
| Average Daily Volume3 Month | 2,484,672 |
| Average Volume | 2,484,672 |
| Average Volume10Days | 1,963,130 |
| Beta | 1.666 |
| Bid | 46.5 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 4.114 |
| City | Morrisville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 53.93 |
| Current Ratio | 4.267 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 55.53 |
| Day Low | 53.83 |
| Debt To Equity | 124.89 |
| Display Name | TG Therapeutics |
| Earnings Call Timestamp End | 1,785,760,200 |
| Earnings Call Timestamp Start | 1,785,760,200 |
| Earnings Growth | -0.706 |
| Earnings Quarterly Growth | -0.724 |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,793,622,600 |
| Earnings Timestamp Start | 1,793,622,600 |
| Ebitda | 136,451,008 |
| Ebitda Margins | 0.17066 |
| Enterprise To Ebitda | 57.545 |
| Enterprise To Revenue | 9.821 |
| Enterprise Value | 7,852,062,720 |
| Eps Current Year | 0.95 |
| Eps Forward | 2.965 |
| Eps Trailing Twelve Months | 2.65 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 212 554 4531 |
| Fifty Day Average | 53.3205 |
| Fifty Day Average Change | 0.6095009 |
| Fifty Day Average Change Percent | 0.011430892 |
| Fifty Two Week Change Percent | 87.42012 |
| Fifty Two Week High | 59.3 |
| Fifty Two Week High Change | -5.369999 |
| Fifty Two Week High Change Percent | -0.09055647 |
| Fifty Two Week Low | 26.76 |
| Fifty Two Week Low Change | 27.17 |
| Fifty Two Week Low Change Percent | 1.0153214 |
| Fifty Two Week Range | 26.76 - 59.3 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,272,893,400,000 |
| Float Shares | 135,238,006 |
| Forward Eps | 2.965 |
| Forward P E | 18.188871 |
| Free Cashflow | 59,134,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 399 |
| Fullday Change | -1.79 |
| Fullday Change Percent | -3.21249 |
| Fullday Price | 54.03 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.82372004 |
| Gross Profits | 658,596,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07469 |
| Held Percent Institutions | 0.74147004 |
| Implied Shares Outstanding | 153,069,053 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,335,744,000 |
| Last Split Factor | 100:5625 |
| Long Business Summary | TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina. |
| Long Name | TG Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 8,255,014,400 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_143627354 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 441,489,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,529,007,633 |
| Number Of Analyst Opinions | 7 |
| Open | 55.53 |
| Operating Cashflow | 17,876,000 |
| Operating Margins | 0.090179995 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.61 |
| Phone | 212 554 4484 |
| Post Market Change | 0.099998474 |
| Post Market Change Percent | 0.18542272 |
| Post Market Price | 54.03 |
| Post Market Time | 1,787,960,793 |
| Previous Close | 55.72 |
| Price Eps Current Year | 56.76842 |
| Price Hint | 2 |
| Price To Book | 13.108897 |
| Price To Sales Trailing12 Months | 10.324757 |
| Profit Margins | 0.55218 |
| Quick Ratio | 3.552 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.79 |
| Regular Market Change Percent | -3.21249 |
| Regular Market Day High | 55.53 |
| Regular Market Day Low | 53.83 |
| Regular Market Day Range | 53.83 - 55.53 |
| Regular Market Open | 55.53 |
| Regular Market Previous Close | 55.72 |
| Regular Market Price | 53.93 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,030,693 |
| Return On Assets | 0.07276 |
| Return On Equity | 1.0028 |
| Revenue Growth | 0.703 |
| Revenue Per Share | 5.61 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 153,069,053 |
| Shares Percent Shares Out | 0.1967 |
| Shares Short | 30,109,741 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 30,686,240 |
| Short Name | TG Therapeutics, Inc. |
| Short Percent Of Float | 0.2843 |
| Short Ratio | 13.3 |
| Source Interval | 15 |
| State | NC |
| Symbol | TGTX |
| Target High Price | 86.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 69.71429 |
| Target Median Price | 75.0 |
| Total Cash | 552,248,000 |
| Total Cash Per Share | 3.893 |
| Total Debt | 754,441,024 |
| Total Revenue | 799,536,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.65 |
| Trailing P E | 20.350943 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 38.272224 |
| Two Hundred Day Average Change | 15.657776 |
| Two Hundred Day Average Change Percent | 0.4091159 |
| Type Disp | Equity |
| Volume | 1,030,693 |
| Website | https://www.tgtherapeutics.com |
| Zip | 27,560 |